APA (7th ed.) Citation

L, R., S, F., K, P., A, S., LE, R., G, Y., . . . WR, D. (2026). Tildrakizumab for the prophylaxis of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood advances, 10(8), 2698. https://doi.org/10.1182/bloodadvances.2025019065

Chicago Style (17th ed.) Citation

L, Runaas, et al. "Tildrakizumab for the Prophylaxis of Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell Transplantation." Blood Advances 10, no. 8 (2026): 2698. https://doi.org/10.1182/bloodadvances.2025019065.

MLA (9th ed.) Citation

L, Runaas, et al. "Tildrakizumab for the Prophylaxis of Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell Transplantation." Blood Advances, vol. 10, no. 8, 2026, p. 2698, https://doi.org/10.1182/bloodadvances.2025019065.